key: cord-0783932-yrpcjrly
authors: Cavalcante, João L.; Shaw, Kirsten E.; Gössl, Mario
title: Cardiac Magnetic Resonance Imaging Midterm Follow Up of COVID-19 Vaccine–Associated Myocarditis
date: 2022-03-16
journal: JACC Cardiovasc Imaging
DOI: 10.1016/j.jcmg.2022.01.008
sha: 85c86cb1a34cd8cc38e3f3369ddb9a294e4cbe5e
doc_id: 783932
cord_uid: yrpcjrly

nan

 1 

prognosis is usually favorable, little is known about the longitudinal follow-up and/or midterm prognosis of patients with COVID-19 vaccine-associated myocarditis (COV19VAM). In non-vaccine-related myocarditis, the persistency of nonischemic myocardial injury on cardiac magnetic resonance (CMR) imaging is associated with an increased risk of adverse cardiovascular events. 2 However it is unknown whether the same occurs in COV19VAM. We present CMR imaging findings, as well as clinical characteristics (Table 1) , of 5 adult patients previously affected by COV19VAM ( Figures 1A to 1H , 2A to 2H, 3A to 3H, 4A to 4H, and 5A to 5H). To our knowledge, this is the first systematic longitudinal evaluation of both clinical and imaging data up to 3-month follow-up (median follow-up time from first CMR in this study was 106 days; interquartile range: 75.5-107.5 days) for patients with previous COV19VAM. There was interval improvement of nonischemic fibrosis seen on late gadolinium enhancement (LGE), albeit fibrosis was still present in 80% of patients. Although this finding could represent vulnerability for adverse cardiovascular long-term events, there were no unfavorable atrial or ventricular arrhythmias seen on a 2-week event monitor placed at 3-month follow-up from the initial diagnosis. Studies of non-vaccine-related myocarditis have demonstrated that persistence of LGE at a median follow-up of 4.7 years is a predictor of allcause mortality and cardiac mortality. 3 Although there is no current consensus on a timeline for repeat CMR imaging for patients affected by COV19VAM, our study highlights the need for ongoing longitudinal clinical evaluation in those patients with persistent LGE, to understand the long-term risks and prognosis of these patients more clearly.

Dr Cavalcante has reported research support from Circle Cardiovascular Imaging and Siemens Healthineers. Dr Gössl has reported consulting for Abbott Vascular. Dr Shaw has reported that she has no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Mario Gössl, Minneapolis Heart Institute Foundation, 920 East 28th Street, #300, Minneapolis, Minnesota 55407, USA. E-mail: mario.goessl@allina.com. Twitter: @MHIValveDoc.

Myocarditis with COVID-19 mRNA vaccines

Cardiac Magnetic Resonance Working Group of the Italian Society of Cardiology. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function